Founded in 1990 and headquartered in Foster City, California, Geron Corporation is a commercial-stage biopharmaceutical company focused on oncology therapeutics. The company's primary product is RYTELO (imetelstat), a telomerase inhibitor approved for treating adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) who have transfusion-dependent anemia. RYTELO represents Geron's first marketed therapeutic and constitutes the company's primary revenue stream.
Geron operates in the biopharmaceutical sector, with commercial operations centered on promoting and distributing RYTELO in the United States market. The company is incorporated in Delaware and trades on the Nasdaq exchange under the ticker GERN. As a commercial-stage enterprise with limited marketed products, Geron's scale remains relatively modest compared to established pharmaceutical manufacturers, with operations concentrated in North America.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-0.13 | $-0.13 | +51.9% | |
| 2024 | $-0.27 | $-0.27 | +15.6% | |
| 2023 | $-0.32 | $-0.32 | +13.5% | |
| 2022 | $-0.37 | $-0.37 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | $-0.18 | $-0.18 | +5.3% | |
| 2016 | $-0.19 | $-0.19 | — | |
| 2015 | $0.00 | $0.00 | — | |
| 2014 | — | — | — | |
| 2013 | — | — | — | |
| 2012 | — | — | — | |
| 2011 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-03-02 | 0000886744-26-000008 | SEC ↗ |
| 2024-12-31 | 2025-02-27 | 0000950170-25-027982 | SEC ↗ |
| 2023-12-31 | 2024-02-28 | 0000950170-24-022056 | SEC ↗ |
| 2022-12-31 | 2023-03-16 | 0000950170-23-008437 | SEC ↗ |
| 2021-12-31 | 2022-03-10 | 0001564590-22-009627 | SEC ↗ |
| 2020-12-31 | 2021-03-11 | 0001564590-21-012493 | SEC ↗ |
| 2019-12-31 | 2020-03-12 | 0001564590-20-010449 | SEC ↗ |
| 2018-12-31 | 2019-03-07 | 0001564590-19-006759 | SEC ↗ |
| 2017-12-31 | 2018-03-16 | 0001564590-18-006051 | SEC ↗ |
| 2016-12-31 | 2017-03-01 | 0001047469-17-001123 | SEC ↗ |
| 2015-12-31 | 2016-03-10 | 0001047469-16-010984 | SEC ↗ |
| 2014-12-31 | 2015-03-11 | 0001047469-15-001989 | SEC ↗ |
| 2013-12-31 | 2014-03-17 | 0001047469-14-002454 | SEC ↗ |
| 2012-12-31 | 2013-03-15 | 0001047469-13-002849 | SEC ↗ |
| 2011-12-31 | 2012-03-07 | 0001206774-12-000967 | SEC ↗ |
| 2010-12-31 | 2011-02-25 | 0001206774-11-000317 | SEC ↗ |
| 2009-12-31 | 2010-02-26 | 0001206774-10-000410 | SEC ↗ |